Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Significantly Higher Trading Volume

About 761,263 shares traded or 7.57% up from the average. It has outperformed by 91.73% the S&P500. Sterling Investment Advisors Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 11.2% in the second quarter. Regeneron Pharmaceuticals now has $48.23B valuation. The stock declined 5.16% or $24.33 reaching $447.16 on the news. Panmure Gordon maintained the shares of ABC in report on Monday, September 26 with “Sell” rating. Regeneron Pharmaceuticals has an average rating of “Hold” and an average target price of $496.35. It has outperformed by 16.14% the S&P500.

Among 9 analysts covering Epizyme (NASDAQ:EPZM), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 30% are positive. The rating was downgraded by Wells Fargo to “Market Perform” on Wednesday, April 20. The firm has “Buy” rating given on Friday, June 9 by J.P. Morgan. (NASDAQ:REGN) by 11.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, August 5. H.C. Wainwright upgraded it to “Buy” rating and $25 target in Monday, March 14 report. As per Wednesday, August 16, the company rating was initiated by Evercore. Roth Capital initiated the stock with “Buy” rating in Friday, September 23 report. The company was maintained on Friday, August 4 by UBS.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.29, from 0.96 in 2016Q3.

In related news, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. 65 funds opened positions while 115 raised stakes. Segall Bryant Hamill Ltd, a Illinois-based fund reported 1,047 shares. Following the completion of the transaction, the senior vice president now directly owns 9,099 shares in the company, valued at approximately $4,335,218.55. Liberty Mutual Group Inc Asset Mgmt Inc owns 0.06% invested in Williams-Sonoma, Inc. Natl Bank Of America De holds 10,017 shares or 0% of its portfolio. Ig Investment Mngmt Ltd holds 0.01% or 5,600 shares in its portfolio. Voya Invest Ltd Co invested 0.02% in Epizyme Inc (NASDAQ:EPZM). Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Independent Portfolio Consultants Inc owns 63 shares. Proshare Lc accumulated 8,356 shares. State Street reported 1.09 million shares stake. 4 are owned by Tarbox. 139,839 were reported by Parametric Port Associate Ltd Liability Corp. Brown Advisory has 4,151 shares for 0% of their portfolio.

Epizyme, Inc.is a clinical-stage biopharmaceutical company. The stock has a market cap of $36.33 billion, a price-to-earnings ratio of 50.54 and a beta of 1.80. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. On Thursday, August 25 the stock rating was maintained by Deutsche Bank with “Hold”. Next Financial Group, Inc controls 835 shares with a value of $410,000,000.

Allstate Corp decreased Gallagher Arthur J & Co (NYSE:AJG) stake by 76,974 shares to 44,776 valued at $2.33M in 2016Q4. Comcast (NASDAQ:CMCSA) was reduced too.

Among 28 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded up 1.71% during midday trading on Friday, hitting $346.59. Therefore 50% are positive. The original version of this news story can be read at https://baseballnewssource.com/markets/citigroup-inc-reiterates-buy-rating-for-regeneron-pharmaceuticals-inc-regn/1620835.html. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Hold” rating given on Thursday, August 3 by BMO Capital Markets. The firm has “Overweight” rating given on Tuesday, September 13 by KeyBanc Capital Markets.

Regeneron Pharmaceuticals, Inc. shares had a trading volume of 1,954K by the end of trading on Tuesday. The rating was maintained by Stifel Nicolaus on Monday, March 7 with “Hold”. The stock now has a consensus rating of “Hold” and a consensus price target of $496.35. Credit Suisse upgraded the shares of REGN in report on Tuesday, December 20 to “Outperform” rating. BlackRock Inc. grew its stake in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BROWN MICHAEL S also sold $1.35 million worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Friday, May 12. In the last ninety days, insiders have sold 129,257 shares of company stock worth $61,745,394. $1.35M worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was sold by STAHL NEIL. BidaskClub downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.39, from 1.06 in 2016Q3. The stock was bought at an average price of $480.93 per share, with a total value of $80,033,965.95.

These funds have shifted positions in (REGN). Bridgewater LP holds 0.02% or 42,300 shares. News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals, Inc. with MarketBeat.com’s FREE daily email newsletter. Commonwealth Of Pennsylvania Pub School Empls Retrmt Sys accumulated 4,334 shares or 0.03% of the stock. Morgan Stanley reported 363,205 shares. Moreover, Teacher Retirement Systems Of Texas has 0.12% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 44,156 shares. 711 are held by Miles Capital.

Marshall Wace Limited Liability Partnership has invested 0.06% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Regeneron Pharmaceuticals now has a consensus rating of Hold and a consensus target price of $496.35. Imperial Capital maintained the stock with “Outperform” rating in Monday, October 31 report. Ftb Advisors holds 53 shares. Henderson Gru Public Limited Com owns 9,822 shares or 0.03% of their USA portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *